AKSO Announces Publication of Preclinical Data Demonstrating Engineered Soluble BCMA Decoy Receptor AB001 Effectively Inhibits Multiple Myeloma and Diffuse Large B Cell Lymphoma - Yahoo Finance
7/27/2022 12:00:00 AM2 years 9 months ago
by Business Wire
by Business Wire
LOS ANGELES & LONDON & BEIJING, July 27, 2022--AKSO Announces Publication of Preclinical Data for DEEP Engineered Soluble BCMA Decoy Receptor AB001
- AB001 is an engineered high-affinity soluble BCMA decoy receptor that traps APRIL and BAFF, critical cytokines controlling B cell development and survival - AB001 effectively inhibits the developm… [+3872 chars]
full article...